6 Cara Therapeutics Analyst Ratings, Earnings, Dividends and Insider Trades | $CARA | NASDAQ:CARA | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Cara Therapeutics Company Profile (NASDAQ:CARA) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Cara Therapeutics (NASDAQ:CARA) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 6 Buy Rating(s)Consensus Rating:Buy (Score: 3.00)Consensus Price Target: $24.00 (20.00% upside) Analysts' Ratings History for Cara Therapeutics (NASDAQ:CARA) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare2/27/2014Needham & Company LLCInitiated CoverageBuyView 2/27/2014Needham & CompanyInitiated CoverageBuy$27.00View 2/25/2014Stifel NicolausInitiated CoverageBuy$21.00View 2/25/2014Canaccord GenuityInitiated CoverageBuy -> Buy$25.00View 2/25/2014Janney Montgomery ScottInitiated CoverageBuyView 2/25/2014Piper JaffrayInitiated CoverageOverweight$23.00View (Data available from 3/9/2012 forward) Earnings History for Cara Therapeutics (NASDAQ:CARA)No earnings announcements for this company have been tracked by Analyst Ratings Network Dividend History for Cara Therapeutics (NASDAQ:CARA)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Cara Therapeutics (NASDAQ:CARA)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare2/5/2014Ventures Vi Lp RhoMajor ShareholderBuy225,818$11.00$2,483,998.00View (Data available from 1/1/2013 forward) About Cara Therapeutics Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors. The Company is developing a class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects associated with available pain therapeutics. The Company is also developing an oral version of CR845, or Oral CR845, for acute and chronic pain, for which it has completed a Phase I clinical trial to demonstrate the ability to deliver CR845 orally. Headlines: (2/28) Cara Therapeutics (CARA) Zooms: Stock Up 12.4% (2/28) Cara Therapeutics (CARA) Zooms: Stock Up 12.4% - Tale of the Tape (2/26) RDInvesting Provides Investors with Free In-Depth Equity Reports on CARA, KIN, OESX and RARE (2/10) XFRA FRA:New Instruments available on XETRA - 11.02.2014-001 (3/5) Oral Proteins and Peptides Market, 2014 - 2024 (2/25) Frontrunning: February 25 Industry, Sector and Symbol: Sector: N/A Industry: N/A Sub-Industry: N/A Exchange: NASDAQ Symbol: CARA CUSIP: Key Metrics: Previous Close: $21.1950 Day Moving Average: $18.789200 Day Moving Average: $18.789 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $436.8MCurrent Quarter EPS Consensus Estimate: $-0.59 EPS Additional Links: View CARA on Google FinanceView CARA on Yahoo FinanceView CARA's Company Profile on ReutersSearch for Cara Therapeutics Inc on Google Cara Therapeutics (NASDAQ:CARA) Chart for Sunday, March, 9, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.